Adaptación y cambio de uso de la Llotja del Mar a edificio cultural

Este proyecto va a tratar del cambio de uso y de la adaptación de un edificio de uso administrativo a un edificio dedicado a las bellas artes de uso cultural y docente. El edificio es la Llotja del Mar y actualmente es la sede de la Camara de Comercio de Barcelona. El edificio actualmente tiene un uso administrativo; en su adaptación vamos a realizar un cambio para que sea de uso docente y de exposición en su mayoria. La escuela de bellas artes a plantear consta de varias secciones, cada una de ellas dedicadas a una disciplina en particular, a saber: pintura, escultura, fotografía y artes escénicas. El trabajo de este proyecto va a consistir en explicar esta adaptación dando todos los datos necesarios para su correcto entendimiento, y conseguir la funcionalidad del nuevo edificio

Monitoring of RAS mutant clones in plasma of patients with RAS mutant metastatic colorectal cancer

Circulating tumor DNA; Liquid biopsy; Metastatic colorectal cancerADN tumoral circulante; Biopsia liquida; Cáncer colorrectal metastásicoADN tumoral circulant; Biòpsia líquida; Càncer colorectal metastàticPurpose Some patients with histologically confirmed primary mCRC and mutated RAS reported undetectable RAS mutant clones in plasma after receiving anti-VEGF treatment. The aim was to prospectively assess it with its potential therapeutic implications. Methods RAS mutant genes in solid biopsy (before first-line treatment: FOLFOX/CAPOX + bevacizumab) were compared in liquid biopsy (before second-line treatment: panitumumab + FOLFIRI), using Idylla™ system. Discordant results between solid/liquid biopsies were assessed by the next-generation sequencing (NGS) test (solid/liquid biopsies). Results Twenty-three patients were assessed (seven had RAS mutant discrepancies between solid/liquid biopsies). The NGS test confirmed that 3/23 (13%) patients had undetectable RAS mutant clones in liquid biopsy and 3/23 (13%) presented discrepancies in solid biopsy (Idylla™ system vs. NGS test). Conclusion Thirteen percentage of patients had undetectable RAS mutant clones in liquid biopsy after first-line treatment. However, some discrepancies between solid and liquid biopsies have been observed. These results suggest a need to improve accuracy of RAS analyses, especially in solid biopsies.This work was supported by Amgen S.A. Amgen did not have any role in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication

Análisis del comportamiento del usuario universitario de tablets

La evolución del mercado y del consumidor requiere que las empresas se orienten hacia el marketing en lugar de otras estrategias. Conocer y analizar las necesidades y deseos de los consumidores para poder satisfacerlas de una forma más efectiva y eficiente que el resto de competidores es la clave para conseguir los objetivos marcados. Este trabajo analiza el comportamiento de los usuarios universitarios de tablets, y través de una encuesta, se persigue conocer con mayor profundidad sus características desde la perspectiva de la compra, el uso y el conocimiento de marca. Con este objetivo en mente, la investigación llevada a cabo se centra en la búsqueda de información para contestar a estos aspectos en base a unas dimensiones que se centran en quién, qué, cómo, para qué, cuándo, dónde y cuánto

Impact of climate change on heating and cooling energy demand in a residential building in a Mediterranean climate

[EN] A range of energy improvement measures applied to a typical Mediterranean residential building are modelled under various climate-change scenarios. Global Circulation Models (CNRM-CM5 and MPI-ESMLR), under two emission scenarios (RCP4.5 and RCP8.5), downscaled by the Spanish Meteorological Agency, are used to generate four temperature projections. Energy simulations are obtained with TRNSYS tools in a Mediterranean climate based on temperature projections in two periods: 2048-2052 and 2096-2100, with the same time span. Various energy measures apply thermal improvements to a conventional residential building model that complies with current regulations for this analysis of best practice in passive construction solutions. Sequential implementation of eight different energy improvements measures are applied to the initial building model: six passives (infiltration, insulation thickness, glazing and frame type, window area, shading devices and natural cross ventilation) and two active (mechanical ventilation and a heat recovery system) measures. The climatic trends that are predicted show a local scenario with a warming climate and the thermal behaviour of the building is shown to differ in each scenario. The demand for indoor heating decreases significantly when the outdoor temperature increases, while the demand for cooling and the risk of overheating increase considerably in all the scenarios. The data for the building conditions that are projected in this study predict that natural and forced ventilation strategies will have the least impact, while increased thermal insulation and reductions in infiltration will have a greater effect on global energy demand.Pérez-Andreu, V.; Aparicio Fernandez, CS.; Martínez-Ibernón, A.; Vivancos, J. (2018). Impact of climate change on heating and cooling energy demand in a residential building in a Mediterranean climate. Energy. 165:63-74. https://doi.org/10.1016/j.energy.2018.09.015S637416

Detection and discrimination of organophosphorus pesticides in water by using a colorimetric probe array

[EN] Detection and discrimination of several organophosphorus pesticides in water using a colorimetric probe array containing twelve dyes has been achieved. A clear discrimination for malathion, leptophos, dichlorvos, dibrom and diazinon was observed. The array was used to determine the concentration of diazinon in orange leavesThe financial support from the Spanish Government (project MAT2012-38429-C04), the Generalitat Valenciana (project PROM-ETEO/2009/016) and the Universitat Politecnica de Valencia (project ref. 2711) is gratefully acknowledged. SCSIE (Universidad de Valencia) is also acknowledged for all the equipment employed.Ferri, D.; Gaviña, P.; Costero, AM.; Parra, M.; Vivancos, J.; Martínez-Máñez, R. (2014). Detection and discrimination of organophosphorus pesticides in water by using a colorimetric probe array. Sensors and Actuators B Chemical. 202:727-731. https://doi.org/10.1016/j.snb.2014.06.011S72773120

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer

Cáncer de mama metastásico; Biomarcadores; CapecitabinaCàncer de mama metastàtic; Biomarcadors; CapecitabinaMetastatic breast cancer; Biomarkers; CapecitabinePurpose: Neratinib plus capecitabine (N+C) demonstrated significant progression-free survival (PFS) benefit in NALA (NCT01808573), a randomized phase III trial comparing N+C with lapatinib + capecitabine (L+C) in 621 patients with HER2-positive (HER2+) metastatic breast cancer (MBC) who had received ≥2 prior HER2-directed regimens in the metastatic setting. We evaluated correlations between exploratory biomarkers and PFS. Patients and Methods: Somatic mutations were evaluated by next-generation sequencing on primary or metastatic samples. HER2 protein expression was evaluated by central IHC, H-score, and VeraTag/HERmark. p95 expression (truncated HER2) was measured by VeraTag. HRs were estimated using unstratified Cox proportional hazards models. Results: Four hundred and twenty samples had successful sequencing: 34.0% had PIK3CA mutations and 5.5% had HER2 (ERBB2) mutations. In the combined patient populations, PIK3CA mutations trended toward shorter PFS [wild-type vs. mutant, HR = 0.81; 95% confidence interval (CI), 0.64–1.03], whereas HER2 mutations trended toward longer PFS [HR = 1.69 (95% CI, 0.97–3.29)]. Higher HER2 protein expression was associated with longer PFS [IHC 3+ vs. 2+, HR = 0.67 (0.54–0.82); H-score ≥240 versus <240, HR = 0.77 (0.63–0.93); HERmark positive vs. negative, HR = 0.76 (0.59–0.98)]. Patients whose tumors had higher HER2 protein expression (any method) derived an increased benefit from N+C compared with L+C [IHC 3+, HR = 0.64 (0.51–0.81); H-score ≥ 240, HR = 0.54 (0.41–0.72); HERmark positive, HR = 0.65 (0.50–0.84)], as did patients with high p95 [p95 ≥2.8 relative fluorescence (RF)/mm2, HR = 0.66 (0.50–0.86) vs. p95 < 2.8 RF/mm2, HR = 0.91 (0.61–1.36)]. Conclusions: PIK3CA mutations were associated with shorter PFS whereas higher HER2 expression was associated with longer PFS. Higher HER2 protein expression was also associated with a greater benefit for N+C compared with L+C.This work was supported by Puma Biotechnology Inc. (no grant number is applicable)

Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples

Biopsy; KRAS mutation; Colorectal cancerBiòpsia; Mutació KRAS, Càncer colorectalBiopsia; Mutación KRAS, Cáncer colorrectalKRAS mutations are common in colorectal cancer (CRC). In this setting, mutation status determination in circulating-free DNA from blood samples (liquid biopsy) has been shown to be a viable alternative to tissue testing. The objective of this study was to compare the sensitivity of two liquid biopsy methods for detecting KRAS mutations in plasma samples from metastatic CRC patients. Samples with a positive (KRAS-MUT+) result and a mutant allelic fraction (MAF) < 5% according to the OncoBEAM RAS CRC assay were pairly analyzed by the Idylla ctKRAS Mutation Test (n = 116). In a cohort of 71 patients with at least 1 year of follow-up, the progression-free survival (PFS) was determined according to MAF values. Idylla detected KRAS mutations in 81/116 OncoBEAM KRAS-MUT+ samples with MAF < 5% and in 48/79 samples with MAF < 1%. Concordance between OncoBEAM and Idylla significantly improved at higher MAF values. PFS rates at 6 and 12 months tended to be lower in patients with MAF levels between 1% and 5% than in those with levels <1%. OncoBEAM demonstrated greater sensitivity for plasma detection of KRAS mutations than Idylla. Importantly, our data identified a "gray zone" below 1% MAF where Idylla showed reduced KRAS mutation detection, highlighting the importance of an accurate method to provide the mutational status of CRC patients

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial

Biomarker; Breast cancer; Gene expressionBiomarcador; Càncer de mama; Expressió gènicaBiomarcador; Cáncer de mama; Expresión génicaBackground HER2DX is a prognostic and predictive assay in early-stage HER2-positive breast cancer based on clinical features and the expression of 4 gene signatures (immune, proliferation, luminal differentiation and HER2 amplicon), including ERBB2 mRNA levels. Here, we evaluated the ability of HER2DX to predict efficacy of a de-escalated, chemotherapy-free neoadjuvant regimen in HER2-positive/hormone receptor-positive breast cancer. Methods HER2DX was evaluated on pre-treatment tumour samples from the PerELISA phase II study focused on postmenopausal patients with operable HER2-positive/hormone receptor-positive breast cancer. Patients received 2-weeks of letrozole, and then underwent a re-biopsy for Ki67 evaluation. Patients with endocrine therapy sensitive disease (ESD) (i.e., >20.0% Ki67 relative reduction at week 2) continued letrozole and 5 cycles of trastuzumab and pertuzumab. Primary aim was to test the ability of HER2DX risk-score, HER2DX pCR score and HER2DX ERBB2 mRNA score (as continuous variables and group categories) to predict pathological complete response (pCR) in patients with ESD. Logistic regression and receiver–operator curve (ROC) analysis assessed associations of HER2DX scores with pCR and ESD. Findings HER2DX was evaluated in 55 patients (86.0%) enrolled in PerELISA and 40 patients (73.0%) had ESD. The pCR rate in patients with ESD was 22.5% (9/40). In this group, HER2DX pCR score and HER2DX ERBB2 mRNA score were significantly associated with pCR (p = 0.008 and p = 0.003, univariate logistic regression model; area under ROC [AUC] = 0.803 and 0.896). The pCR rate in low, medium, and high HER2DX pCR score groups was 7.7% (2/26), 46.2% (6/13) and 100.0% (1/1), respectively. The pCR rate in low, medium, and high HER2DX ERBB2 score groups was 0.0% (0/12), 7.7% (1/13) and 53.3% (8/15), respectively. HER2DX pCR score was also significantly associated with Ki-67 response following 2-weeks of letrozole (p = 0.002, univariate logistic regression model; AUC = 0.775). The rate of ESD in low, medium, and high HER2DX pCR score groups was 89.7% (26/29), 65.0% (13/20) and 16.7% (1/6), respectively. Interpretation HER2DX predicts response following neoadjuvant letrozole in combination with dual HER2 blockade with trastuzumab and pertuzumab in early-stage HER2-positive/hormone receptor-positive breast cancer.This study received funding from Reveal Genomics

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

Anàlisi de seqüències d'ADN; Subtipus PAM50; Genètica molecularAnálisis de secuencias de ADN; Subtipo PAM50; Genética molecularDNA sequence analyses; PAM50 subtype; Molecular geneticBackground: The SOLTI-1301 AGATA study aimed to assess the feasibility of a multi-institutional molecular screening program to better characterize the genomic landscape of advanced breast cancer (ABC) and to facilitate patient access to matched-targeted therapies in Spain. Methods: DNA sequencing of 74 cancer-related genes was performed using FFPE tumor samples in three different laboratories with three different gene panels. A multidisciplinary advisory board prospectively recommended potential targeted treatments. The primary objective was to determine the success of matching somatic DNA alteration to an experimental drug/drug class. Results: Between September 2014 and July 2017, 305 patients with ABC from 10 institutions were enrolled. Tumor sequencing was successful in 260 (85.3%) patients. Median age was 54 (29-80); most tumors were hormone receptor-positive/HER2-negative (74%), followed by triple-negative (14.5%) and HER2-positive (11.5%). Ninety-seven (37%) tumor samples analyzed proceeded from metastatic sites. Somatic mutations were identified in 163 (62.7%) patients, mostly in PIK3CA (34%), TP53 (22%), AKT1 (5%), ESR1 (3%), and ERBB2 (3%) genes. Significant enrichment of AKT1 mutation was observed in metastatic versus primary samples (9% vs. 2%; p=0.01). Genome-driven cancer therapy was recommended in 45% (n=116) of successfully screened patients, 11% (n=13) of whom finally received it. Among these patients, 46.2% had a PFS of ≥6 months on matched therapy. Conclusions: AGATA is the first nationwide molecular screening program carried out in Spain and we proved that implementing molecular data in the management of ABC is feasible. Although these results are promising, only 11% of the patients with genome-driven cancer therapy received it.This study was supported by a grant from Novartis. This study was funded, in part, by the project PI 15/01508, integrated in the Plan Estatal I+D+I and co-funded by Instituto de Salud Carlos III - Subdirección General de Evaluación and European Regional Development Fund (ERDF) (to EC) and by a grant from Mutua Madrileña Foundation (to EC). The decisions and responsibilities of this study were all under the sponsor: SOLTI Breast Cancer Research Group

Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer

Malignitats ginecològiques; Fracció al·lel mutant; PI3KNeoplasias ginecológicas; Fracción alélica mutante; PI3KGynecologic malignancies; Mutant allele fraction; PI3KObjectives Aberrant PI3K/AKT/mTOR activation is common in gynaecological malignancies. However, predictive biomarkers of response to PI3K pathway inhibitors (PAMi) have yet to be identified. Methods We analysed the outcomes of patients with advanced gynaecological cancer with available genomic data, treated with PAMi as single agents or in combination in phase I clinical trials. Clinical relevance of the PIK3CA mutant allele fraction (MAF) was investigated. MAF of each variant was normalised for tumour purity in the sample (adjMAFs) to infer clonality of PIK3CA mutations, defined as clonal (≥0.4) or subclonal (<0.4). Results A total of 50 patients with gynaecological cancer (24 ovarian; 15 endometrial; 11 cervical) with available targeted mutation profiling were selected. PAMi therapy was matched to PIK3CA/PTEN mutation in 30 patients (60%). The overall response rate, median time to progression (mTTP) and clinical benefit rate (CBR) of the entire population were 10% (N=5), 3.57 months (2.57–4.4) and 40% (N=18), respectively. Genotype-matched therapy did not lead to a favourable CBR (OR 0.91, p=1 (0.2–3.7)) or mTTP (3.57 months (2.6–4.4) vs 3.73 months (1.9–13.2); HR 1.41; p=0.29). We did not detect differences in mTTP according to therapy or PIK3CA codon mutation (HR 1.71, p=0.24). Overall, 41% of patients had a TTP ratio (TTP PAMi/TTP on immediately prior or subsequent palliative chemotherapy) ≥1.3, without statistically significant differences according to tumour type (p=0.39), molecular alteration status (p=0.13) or therapy (p=0.54). In univariate analysis, genotype-matched therapy in patients with PIK3CA clonal events was associated with improved mTTP (HR 3.6; p=0.03). Conclusions Our study demonstrates that patients with advanced gynaecological cancer, refractory to standard therapies, achieved meaningful clinical benefit from PAMi. The impact of PI3KCA clonality on response to selected PAMi in patients with gynaecological cancer deserves further investigation